IP Library Granted Patent US 10,668,157
Granted Patent B2
US 10,668,157 · App. 15/304,409 · Granted Jun 2, 2020

Anionic drug-containing medical device

Inventors: Haruka Obata (Tokyo, JP); Kiyoshi Shoji (Tokyo, JP); Yoshiko Yamazaki (Tokyo, JP); Toru Matsunaga (Tokyo, JP); Takao Sato (Tokyo, JP); Wakiko Asayama (Kobe, JP); Shinichi Yasueda (Kobe, JP)
Assignees: SEED CO., LTD.; SENJU PHARMACEUTICAL CO., LTD.
A61K47/32A61K9/06A61K31/352A61K31/661
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,668,157
App. No.
15/304,409
Granted
Jun 2, 2020
Kind
B2
Abstract

The purpose of the present invention is to provide a polymer gel that can increase drug content ratio and reduce undesirable influence on gel strength and shape stability after the drug release, compared with the conventional techniques. The purpose can be achieved by an anionic drug-containing medical device comprising: (1) an anionic drug; and (2) a copolymer which contains, as constituents, a cationic monomer comprising a condensation product of an alkyl quaternary ammonium compound having a substituted or unsubstituted aralkyl group and (meth)acrylic acid or a salt of the condensation product and a monomer capable of copolymerizing with the condensation product or the salt of the condensation product.

Claims (9)

1. An anionic drug-containing contact lens comprising:

(1) an anionic drug; and

(2) a copolymer which consists of, as constituent, at least one cationic monomer consisting of methacryloxyethyl dimethylbenzyl ammonium chloride, at least one hydrophilic monomer, at least one cross-linking monomer, and optionally at least one hydrophobic monomer,

wherein the compounding ratio of the cationic monomer is between 2.5 and 15 mol % relative to 1 mol of the hydrophilic monomer,

wherein the anionic drug-containing contact lens is a hydrogel,

wherein the at least one hydrophilic monomer is one or more selected from the group consisting of hydroxymethyl (meth)acrylate, 2-hydroxyethyl (meth)acrylate, 2-hydroxypropyl (meth)acrylate, 2,3-dihydroxypropyl (meth)acrylate, 2-polyethyleneglycol mono(meth)acrylate, 2-polypropyleneglycol (meth)acrylate, N,N-dimethyl (meth)acrylamide, N,N-diethyl (meth)acrylamide and N-vinylpyrrolidone.

2. The anionic drug-containing contact lens of claim 1 , wherein the anionic drug is either dexamethasone sodium phosphate or sodium cromoglicate.

3. The anionic drug-containing contact lens of claim 1 , where the anionic drug-containing contact lens was subjected to autoclave sterilization.

4. The anionic drug-containing contact lens of claim 1 , where the anionic drug-containing contact lens was subjected to steam sterilization.

Assignments (2)
CHANGE OF ADDRESS Recorded Aug 24, 2018
From: SENJU PHARMACEUTICAL CO., LTD.
To: SENJU PHARMACEUTICAL CO., LTD.
Reel/Frame 046835/0350 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 1, 2016
From: OBATA, HARUKA; SHOJI, KIYOSHI; YAMAZAKI, YOSHIKO; MATSUNAGA, TORU; SATO, TAKAO; ASAYAMA, WAKIKO; YASUEDA, SHINICHI
To: SEED CO., LTD.; SENJU PHARMACEUTICAL CO., LTD.
Reel/Frame 040185/0297 →
Priority Claims (1)
JP 2014-085664 · Apr 17, 2014 · national
Continuity (1)
Related Publication 20170043017A1 · Feb 16, 2017